Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
01 05 2020
01 05 2020
Historique:
received:
08
10
2019
revised:
18
12
2019
accepted:
19
12
2019
pubmed:
6
2
2020
medline:
25
6
2021
entrez:
4
2
2020
Statut:
ppublish
Résumé
Vancomycin and piperacillin/tazobactam are reported in clinical studies to increase acute kidney injury (AKI). However, no clinical study has demonstrated synergistic toxicity, only that serum creatinine increases. To clarify the potential for synergistic toxicity between vancomycin, piperacillin/tazobactam and vancomycin + piperacillin/tazobactam treatments by quantifying kidney injury in a translational rat model of AKI and using cell studies. (i) Male Sprague-Dawley rats (n = 32) received saline, vancomycin 150 mg/kg/day intravenously, piperacillin/tazobactam 1400 mg/kg/day intraperitoneally or vancomycin + piperacillin/tazobactam for 3 days. Urinary biomarkers and histopathology were analysed. (ii) Cellular injury was assessed in NRK-52E cells using alamarBlue®. Urinary output increased from Day -1 to Day 1 with vancomycin but only after Day 2 for vancomycin + piperacillin/tazobactam-treated rats. Plasma creatinine was elevated from baseline with vancomycin by Day 2 and only by Day 4 for vancomycin + piperacillin/tazobactam. Urinary KIM-1 and clusterin were increased with vancomycin from Day 1 versus controls (P < 0.001) and only on Day 3 with vancomycin + piperacillin/tazobactam (P < 0.001, KIM-1; P < 0.05, clusterin). The histopathology injury score was elevated only in the vancomycin group when compared with piperacillin/tazobactam as a control (P = 0.04) and generally not so with vancomycin + piperacillin/tazobactam. In NRK-52E cells, vancomycin induced cell death with high doses (IC50 48.76 mg/mL) but piperacillin/tazobactam did not, and vancomycin + piperacillin/tazobactam was similar to vancomycin. All groups treated with vancomycin demonstrated AKI; however, vancomycin + piperacillin/tazobactam was not worse than vancomycin. Histopathology suggested that piperacillin/tazobactam did not worsen vancomycin-induced AKI and may even be protective.
Sections du résumé
BACKGROUND
Vancomycin and piperacillin/tazobactam are reported in clinical studies to increase acute kidney injury (AKI). However, no clinical study has demonstrated synergistic toxicity, only that serum creatinine increases.
OBJECTIVES
To clarify the potential for synergistic toxicity between vancomycin, piperacillin/tazobactam and vancomycin + piperacillin/tazobactam treatments by quantifying kidney injury in a translational rat model of AKI and using cell studies.
METHODS
(i) Male Sprague-Dawley rats (n = 32) received saline, vancomycin 150 mg/kg/day intravenously, piperacillin/tazobactam 1400 mg/kg/day intraperitoneally or vancomycin + piperacillin/tazobactam for 3 days. Urinary biomarkers and histopathology were analysed. (ii) Cellular injury was assessed in NRK-52E cells using alamarBlue®.
RESULTS
Urinary output increased from Day -1 to Day 1 with vancomycin but only after Day 2 for vancomycin + piperacillin/tazobactam-treated rats. Plasma creatinine was elevated from baseline with vancomycin by Day 2 and only by Day 4 for vancomycin + piperacillin/tazobactam. Urinary KIM-1 and clusterin were increased with vancomycin from Day 1 versus controls (P < 0.001) and only on Day 3 with vancomycin + piperacillin/tazobactam (P < 0.001, KIM-1; P < 0.05, clusterin). The histopathology injury score was elevated only in the vancomycin group when compared with piperacillin/tazobactam as a control (P = 0.04) and generally not so with vancomycin + piperacillin/tazobactam. In NRK-52E cells, vancomycin induced cell death with high doses (IC50 48.76 mg/mL) but piperacillin/tazobactam did not, and vancomycin + piperacillin/tazobactam was similar to vancomycin.
CONCLUSIONS
All groups treated with vancomycin demonstrated AKI; however, vancomycin + piperacillin/tazobactam was not worse than vancomycin. Histopathology suggested that piperacillin/tazobactam did not worsen vancomycin-induced AKI and may even be protective.
Identifiants
pubmed: 32011685
pii: 5721486
doi: 10.1093/jac/dkz563
pmc: PMC8453375
doi:
Substances chimiques
Anti-Bacterial Agents
0
Piperacillin, Tazobactam Drug Combination
157044-21-8
Vancomycin
6Q205EH1VU
Penicillanic Acid
87-53-6
Piperacillin
X00B0D5O0E
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1228-1236Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK119463
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Biomed Res Int. 2015;2015:704382
pubmed: 26504822
Clin Kidney J. 2013 Feb;6(1):8-14
pubmed: 27818745
Am J Kidney Dis. 1987 Dec;10(6):427-30
pubmed: 3687935
Nephron. 1993;65(1):154-5
pubmed: 8413777
Infect Control Hosp Epidemiol. 2016 Jan;37(1):70-9
pubmed: 26456803
Clin Infect Dis. 2019 Apr 24;68(9):1456-1462
pubmed: 30165426
JAMA. 2018 Feb 27;319(8):788-799
pubmed: 29486041
Toxicol Appl Pharmacol. 2009 Aug 1;238(3):306-14
pubmed: 19371613
Clin Infect Dis. 2020 Jul 11;71(2):426-432
pubmed: 31833540
JAMA. 2018 Sep 11;320(10):984-994
pubmed: 30208454
J Am Soc Nephrol. 2012 Jan;23(1):13-21
pubmed: 22021710
J Am Soc Nephrol. 2017 Jun;28(6):1723-1728
pubmed: 28082518
Nat Biotechnol. 2010 May;28(5):478-85
pubmed: 20458318
F1000Res. 2016 May 24;5:
pubmed: 27239295
Intensive Care Med. 2009 May;35(5):871-81
pubmed: 19066848
Free Radic Biol Med. 2012 May 1;52(9):1865-73
pubmed: 22401854
Pharm Res. 1991 Oct;8(10):1318-22
pubmed: 1796052
Toxicol Appl Pharmacol. 2009 Aug 1;238(3):301-5
pubmed: 19371616
Surg Infect (Larchmt). 2016 Feb;17(1):38-47
pubmed: 26484854
Toxicol Lett. 2017 Aug 5;277:9-17
pubmed: 28549670
Crit Care Med. 2018 Jan;46(1):12-20
pubmed: 29088001
Nephrol Dial Transplant. 2008 Apr;23(4):1203-10
pubmed: 17962378
Ther Drug Monit. 2019 Apr;41(2):213-226
pubmed: 30883514
Antimicrob Agents Chemother. 2019 Jun 24;63(7):
pubmed: 30988153
Antimicrob Agents Chemother. 1989 Jun;33(6):928-32
pubmed: 2764543
Pediatr Crit Care Med. 2017 Dec;18(12):1183-1184
pubmed: 29206737
Clin Infect Dis. 2017 Nov 29;65(12):2137-2143
pubmed: 29020249
J Infect Chemother. 2016 Feb;22(2):78-83
pubmed: 26712584
PLoS One. 2015 Jul 24;10(7):e0133912
pubmed: 26207996
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5742-51
pubmed: 27431226
Antimicrob Agents Chemother. 1999 Jul;43(7):1549-55
pubmed: 10390201
J Antimicrob Chemother. 2019 Aug 1;74(8):2326-2334
pubmed: 31065686
Clin Chim Acta. 2018 Dec;487:15-21
pubmed: 30201372
Ther Adv Endocrinol Metab. 2016 Jun;7(3):136-47
pubmed: 27293542
Toxicol Pathol. 2010 Jun;38(4):666-7
pubmed: 20530250
Toxicol Pathol. 2012 Oct;40(7):1031-48
pubmed: 22581810
Antimicrob Agents Chemother. 1990 Jun;34(6):1020-5
pubmed: 2393261
J Urol. 1975 Dec;114(6):802-8
pubmed: 1195454
Nat Biotechnol. 2010 May;28(5):446-54
pubmed: 20458314
Clin Infect Dis. 2020 Apr 10;70(8):1536-1545
pubmed: 31157370
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28807910
Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98
pubmed: 19106348
Antimicrob Agents Chemother. 1999 May;43(5):1003-12
pubmed: 10223907
Nat Biotechnol. 2010 May;28(5):436-40
pubmed: 20458311
Antimicrob Agents Chemother. 2013 Oct;57(10):5131-3
pubmed: 23836188
J Cell Physiol. 1978 Mar;94(3):335-42
pubmed: 304450